Annexon Biosciences
South San Francisco
About Annexon Biosciences
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $720.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:ANNX
- Website: annexonbio.com
- Phone: (650)822-5500
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/annexon-biosciences-70644 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.